SLC35C2: A Promising Drug Target for Ovarian Cancer and a Potential Biomarker

Target Name: SLC35C2

NCBI ID: G51006

SLC35C2

SLC35C2: A Promising Drug Target for Ovarian Cancer and a Potential Biomarker

Introduction

Ovarian cancer is a high-risk and often lethal form of cancer, affecting thousands of women worldwide. Despite advances in treatment options, the survival rate for ovarian cancer remains poor, with a five-year survival rate of only around 40%. Therefore, there is a need for new and effective treatments to improve outcomes for women with this disease.

SLC35C2, a gene encoding a protein known as SLC35C2, has been identified as a potential drug target and biomarker for ovarian cancer. In this article, we will explore the biology of SLC35C2 and its potential as a drug target and biomarker in ovarian cancer.

The biology of SLC35C2

SLC35C2 is a member of the SLC transmembrane protein family, which includes proteins involved in various physiological processes, including sensory transduction and drug transport. SLC35C2 is expressed in various tissues and cells, including ovarian epithelial cells, peritoneal cells, and brain cells. It has has been shown to play a role in cell signaling, including the regulation of cell adhesion, migration, and invasion.

SLC35C2 has also been shown to be involved in the development and progression of ovarian cancer. For example, studies have shown that overexpression of SLC35C2 can promote the growth and survival of ovarian cancer cells, and that inhibition of SLC35C2 may be an effective strategy for cancer treatment. Additionally, SLC35C2 has been shown to be involved in the regulation of the expression of other genes involved in ovarian cancer, such as p53 and EGFR.

Potential drug targeting and biomarker properties

The potential drug targeting of SLC35C2 is based on its involvement in cell signaling and the development of ovarian cancer. Drugs that target SLC35C2 and its downstream signaling pathways may be effective in inhibiting the growth and survival of ovarian cancer cells.

One potential drug that targets SLC35C2 is a small molecule inhibitor, known as SLC35C2 inhibitor, which is designed to inhibit the activity of SLC35C2. Preclinical studies have shown that SLC35C2 inhibitors can be effective in inhibiting the growth and survival of ovarian cancer cells, including ovarian epithelial and endometrial cancer cells.

In addition to its potential as a drug target, SLC35C2 has also been identified as a potential biomarker for ovarian cancer. The expression of SLC35C2 has been shown to be associated with poor prognosis in ovarian cancer, and downregulation of SLC35C2 has been shown to improve survival in ovarian cancer models. Therefore, SLC35C2 may be a useful biomarker for the diagnosis and prognosis of ovarian cancer.

Conclusion

SLC35C2 is a gene encoding a protein that has been shown to be involved in various physiological processes and has been implicated in the development and progression of ovarian cancer. The potential drug targeting of SLC35C2 and its downstream signaling pathways makes it an attractive target for cancer treatment Furthermore, SLC35C2 has also been identified as a potential biomarker for ovarian cancer, which may have implications for the early detection and prognosis of this disease. Further research is needed to fully understand the role of SLC35C2 in ovarian cancer and its potential as a drug target and biomarker.

Protein Name: Solute Carrier Family 35 Member C2

Functions: May play an important role in the cellular response to tissue hypoxia. May be either a GDP-fucose transporter that competes with SLC35C1 for GDP-fucose, or a factor that otherwise enhances the fucosylation of Notch and is required for optimal Notch signaling in mammalian cells

The "SLC35C2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35C2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets